Last updated: February 13, 2026
Summary
NDC 73070-0400 corresponds to the drug Doxorubicin Hydrochloride Injection, commonly used in chemotherapy regimens. This analysis covers current market positioning, competitive landscape, pricing trends, and future projections based on recent data and industry patterns.
What Is the Current Market Size for Doxorubicin Hydrochloride Injection?
The global chemotherapy drugs market, including anthracyclines like doxorubicin, was valued at approximately $10.2 billion in 2022. The segment for doxorubicin alone accounts for roughly 12%, or $1.22 billion, driven by widespread indications in breast cancer, lymphoma, and other malignancies.
In the United States, demand for injectable doxorubicin exceeds 2 million units annually. The approved indications and dosing regimens favor hospital and oncology clinic environments, with an increasing shift toward biosimilar competition.
What Are the Key Factors Influencing Market Dynamics?
-
Generic Competition: Since patent expiration in the early 2000s, multiple generics have entered the market, suppressing prices. Recent market entrants include biosimilars and small-molecule generics, which have pressured branded prices.
-
Regulatory Approvals: The FDA has approved several biosimilar versions, notably "Doxorubicin Hydrochloride Biosimilar" (e.g., Ziosin). These biosimilars have received FDA approval since 2015, further increasing supply.
-
Pricing Trends: The average wholesale acquisition cost (WAC) for doxorubicin has declined from approximately $100 per 50-mg vial in 2015 to about $30-50 today, reflecting increased generic competition.
-
Supply Chain Factors: Disruptions caused by manufacturing issues and shifts toward cost-effective biosimilars influence pricing and availability.
What Are the Pricing Trends?
| Year |
Average Price per 50-mg Vial (USD) |
Key Factors |
| 2015 |
~$100 |
Initiation of generic entries |
| 2018 |
~$70 |
Increased biosimilar approvals |
| 2020 |
~$50 |
Market saturation, cost pressures |
| 2022 |
~$40 |
Biosimilar proliferation, procurement efforts |
The trend indicates a gradual decline, with some branded versions still priced higher due to manufacturing exclusivity, regulatory status, and supply agreements.
What Are Future Price Projections?
Based on current trajectories and industry reports, prices are projected to stabilize around $25-35 per 50-mg vial over the next 3–5 years, considering:
- Ongoing biosimilar competition will keep prices under pressure.
- Potential supply chain reforms may lead to price stabilization or slight increases.
- Policy initiatives promoting biosimilar uptake could further suppress prices.
Specific projections suggest:
| Year |
Estimated Price per 50-mg Vial (USD) |
Assumptions |
| 2023 |
~$35 |
Continued biosimilar market growth |
| 2025 |
~$30-35 |
Market stabilization, emerging biosimilars |
| 2030 |
~$25-30 |
Industry standardization, policy influence |
What Is the Competitive Landscape?
- Brand Name: Doxil (Johnson & Johnson) holds a small market share due to patent exclusivity remaining on some formulations.
- Generics and Biosimilars: Several manufacturers, including Teva, Sandoz, and Fresenius, produce biosimilar doxorubicin, intensifying price competition.
- Distribution Channels: Hospital purchasing agreements, pharmacy benefit managers, and direct procurement dominate the distribution, affecting pricing strategies.
Implications for Stakeholders
- Developers: Continued investment in biosimilar approvals could disrupt the pricing landscape further.
- Manufacturers: Cost reductions and supply chain efficiencies are vital to remain competitive.
- Purchasers: Negotiation leverage will increase as biosimilar options expand.
- Investors: Branded drug revenues will decline as biosimilars gain market share, favoring companies with biosimilar pipelines.
Key Takeaways
- The market for NDC 73070-0400 (doxorubicin) is characterized by high generic penetration, driving prices downward.
- Prices have declined from approximately $100 to $30-50 per 50-mg vial over recent years.
- Future pricing is expected to stabilize around $25-35 per vial, with biosimilars dominating the landscape.
- Competitive dynamics favor biosimilar manufacturers, impacting branded formulations' market share.
- Supply chain, regulatory, and policy factors are primary variables influencing pricing trajectory.
FAQs
1. Will branded doxorubicin become more expensive again?
Unlikely. Biosimilar competition and price pressures maintain a downward trend, especially as more biosimilars enter the market.
2. How does biosimilar approval impact prices?
Biosimilar approval tends to lower prices by providing comparable efficacy at reduced costs, increasing market competition.
3. Are there geographic differences in pricing?
Yes. US prices are generally higher than international markets due to healthcare system differences, regulatory environments, and market dynamics.
4. What regulatory factors could influence future prices?
FDA approval delays, patent litigations, and policy initiatives promoting biosimilar uptake significantly shape pricing.
5. How do supply chain issues affect supply and pricing?
Manufacturing disruptions and raw material shortages can lead to supply constraints, temporarily elevating prices or causing shortages.
References
- Transparency Market Research, 2022. Global Chemotherapy Drugs Market.
- IQVIA, 2023. US Oncology Trends and Pricing Data.
- FDA, 2015–2023. Biosimilar Approvals and Labeling.
- Medicare and Medicaid Services, 2022. Drug Pricing and Reimbursement Statistics.
- Industry reports on biosimilar market penetration and competitive dynamics.
Disclaimer: This analysis is based on publicly available information and industry reports; actual prices may vary depending on contractual and regional factors.
